medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2010, Number 1

<< Back Next >>

Rev Mex Oftalmol 2010; 84 (1)

Uso de bevacizumab subconjuntival para el manejo de la neovascularización corneal

Garcia-Arroyo E, Macías-Rodríguez Y, Rodríguez-García A

Language: Spanish
References: 12
Page: 5-9
PDF size: 143.43 Kb.


ABSTRACT

Objective:To demonstrate the efficacy of the subconjunctival administration of bevacizumab in the treatment of corneal neovascularization. Methods: This was and interventional, prospective, not randomized study involving 7 eyes with corneal neovascularization due to different causes. All patients received a single dose of 2.5 mg of subconjunctival bevacizumab. Corneal vascularization appearance was photographically documented. Results: 5 of 7 eyes showed an average of 60% regression in the corneal neovascularization as we measured the length of the visible vasculature. Conclusion: Subconjunctival injection of bevacizumab allows an important regression in the corneal neovascularization.


REFERENCES

  1. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987; 6(4):250-257.

  2. Erdurmus M, Totan Y. Graefes Subconjunctival bevacizumab for corneal neovascularization. Arch Clin Exp Ophthalmol 2007; 245(10):1577-1579.

  3. Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007; 55:413-415.

  4. Hosseini H, Nejabat MA. Potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68:799-801.

  5. Amano S, Rohan R y cols. Requirement for Vascular Endothelial Growth Factor in Wound- and Inflammation- Related Corneal Neovascularization. Invest Ophthal Vis Sci 1998; 39(1):18-22.

  6. Doctor PP, Bhat PV, Foster CS. Subconjunctival Bevacizumab for Corneal Neovascularization. Cornea 2008; 27:992- 995.

  7. Bahar I, Kaiserman I, McAllum P y cols. Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Cornea 2008; 27:142-147.

  8. Barbel M. Kenyon EE, Voest CC y cols. A Model of Angiogenesis in the Mouse Cornea. Invest Ophthal Vis Sci, 1996; 37:1625-1632.

  9. Manzano R, Peyman G, Khan P, Carvounis P y cols. Inhibition of experimental corneal neovascularization by Bevacizumab (AVASTIN). Brit J Ophthalmol 2007; 91:804-807.

  10. Kim SW, Ha B, Kim EK, Tchah H y cols. The Effect of Topical Bevacizumab on Corneal Neovascularization. Ophthalmology 2008; 115(6):33-38.

  11. Patrick M, Pan SF, Plambeck S, Ferguson TA. Interactions Regulate Neovascularization in the Cornea. Invest Ophthal Vis Sci 2003; 44:93-98.

  12. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthal Vis Sci 1996; 37(12):2485-2494.




2020     |     www.medigraphic.com